UK Regulators Endorse One Cancer Drug, Reject Another

UK drug regulators recommended coverage of AbbVie’s Venclyxto (venetoclax) by the government’s Cancer Drugs Fund but rejected Bayer’s Stivarga (regorafenib) for inclusion.

Venclyxto was approved by the National Institute for Health and Care Excellence (NICE) for treatment of adults with chronic lymphocytic leukemia.

Bayer sought NICE approval of Stivaga for treatment of unresectable hepatocellular carcinoma in adults who have had sorafenib.